BMO Capital Maintains Bullish 12%+ BrightSpring EBITDA Growth Outlook on Drug Contract Wins, Generic Conversions

BrightSpring Health Services Inc. (NASDAQ:BTSG) is one of the best new stocks to invest in. On November 13, BMO Capital initiated coverage of BrightSpring Health with an Outperform rating and $40 price target. BMO Capital maintains its three-year outlook for BrightSpring to achieve 12%+ EBITDA growth, driven by multiple factors. The firm anticipates a long-term opportunity for BrightSpring to secure additional limited distribution drug contracts and benefit from an increase in generic drug conversions. Ea ...